Oxomemazine free base | CAS# 3689-50-7 | Antihistamine

MedKoo Cat#: 573658 | Name: Oxomemazine free base

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Oxomemazine is an antihistamine and anticholinergic used for the treatment of cough. Oxomemazine is selective for M1 muscarinic receptors. Oxomemazine could be classified as a selective drug for M1 receptors and also demonstrate that rat cerebral microsomes contain three different subtypes of M1, M3 and the other site which is different from M1, M2 and M3 receptors.

Chemical Structure

Oxomemazine free base

CAS#3689-50-7 (free base)

Theoretical Analysis

MedKoo Cat#: 573658

Name: Oxomemazine free base

CAS#: 3689-50-7 (free base)

Chemical Formula: C18H22N2O2S

Exact Mass: 330.1402

Molecular Weight: 330.45

Elemental Analysis: C, 65.43; H, 6.71; N, 8.48; O, 9.68; S, 9.70

Price and Availability

Size	Price	Availability
100mg	USD 350.00	2 Weeks
200mg	USD 550.00	2 Weeks
500mg	USD 950.00	2 Weeks
1g	USD 1,650.00	2 Weeks
2g	USD 2,950.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

3689-50-7 (free base) 4784-40-1 (HCl)

Synonym

RP 6847; RP6847; RP-6847; Oxomemazine free base;

IUPAC/Chemical Name

10-(3-(Dimethylamino)-2-methylpropyl)phenothiazine 5,5-dioxide

InChi Key

QTQPVLDZQVPLGV-UHFFFAOYSA-N

InChi Code

1S/C18H22N2O2S/c1-14(12-19(2)3)13-20-15-8-4-6-10-17(15)23(21,22)18-11-7-5-9-16(18)20/h4-11,14H,12-13H2,1-3H3

SMILES Code

CC(CN1c2ccccc2S(=O)(=O)c3c1cccc3)CN(C)C

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 330.45 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Bedhomme S, Vaillant-Roussel H, Vorilhon P, Lafarge E, Pereton B, Prunet- Spano C, Pereira B, Vennat B, Savanovitch C. Pediatric pharmaceutical interventions in self-medication: a descriptive study in community pharmacies. BMC Prim Care. 2023 Nov 6;24(1):232. doi: 10.1186/s12875-023-02180-9. PMID: 37932731; PMCID: PMC10626637. 2: Raikar P, Gurupadayya B, Rajan S, Koganti S, Mounika P. Enantiomeric separation of oxomemazine in rabbit plasma by ultra-fast LC and application in a stereoselective pharmacokinetic study. Bioanalysis. 2022 Apr;14(8):479-489. doi: 10.4155/bio-2022-0008. Epub 2022 Apr 29. PMID: 35484942. 3: Abdelaleem EA, Abdelwahab NS. Green chromatographic method for analysis of some anti-cough drugs and their toxic impurities with comparison to conventional methods. Saudi Pharm J. 2018 Dec;26(8):1185-1191. doi: 10.1016/j.jsps.2018.07.007. Epub 2018 Jul 25. PMID: 30532640; PMCID: PMC6260482. 4: Zhou J, Luo P, Chen S, Meng L, Sun C, Du Q, Sun F. Enantioseparation of Six Antihistamines with Immobilized Cellulose Chiral Stationary Phase by HPLC. J Chromatogr Sci. 2016 Apr;54(4):531-5. doi: 10.1093/chromsci/bmv177. Epub 2015 Dec 10. PMID: 26657408; PMCID: PMC4885385. 5: Mohamed AM, Abdelmageed OH, Salem H, Nagy DM, Omar MA. Spectrofluorimetric determination of certain biologically active phenothiazines in commercial dosage forms and human plasma. Luminescence. 2013 May-Jun;28(3):345-54. doi: 10.1002/bio.2388. Epub 2012 Jul 12. PMID: 22786713. 6: Siddegowda MS, Butcher RJ, Akkurt M, Yathirajan HS, Ramesh AR. Oxomemazine hydro-chloride. Acta Crystallogr Sect E Struct Rep Online. 2011 Aug 1;67(Pt 8):o1875. doi: 10.1107/S1600536811025372. Epub 2011 Jul 2. PMID: 22090928; PMCID: PMC3212271. 7: Pajak B, Molnar J, Engi H, Orzechowski A. Preliminary studies on phenothiazine-mediated reversal of multidrug resistance in mouse lymphoma and COLO 320 cells. In Vivo. 2005 Nov-Dec;19(6):1101-4. PMID: 16277030. 8: El-Didamony AM. Extractive spectrophotometric methods for the determination of oxomemazine hydrochloride in bulk and pharmaceutical formulations using bromocresol green, bromocresol purple and bromophenol blue. Arch Pharm (Weinheim). 2005 Apr;338(4):190-7. doi: 10.1002/ardp.200400947. PMID: 15864789. 9: Pujet JC, Keddad K, Sévenier F, Jolivet-Landreau I. Etude comparative de deux antitussifs dans le traitement des toux aiguës sèches d'origine infectieuse (étude prospective, randomisée, en simple aveugle) [Comparative study of two antitussive drugs in the treatment of acute dry cough of infectious origin (prospective, randomized, single blind study)]. Therapie. 2002 Sep- Oct;57(5):457-63. French. PMID: 12611200. 10: Brasseur P, Lecoublet S, Kapel N, Favennec L, Ballet JJ. In vitro evaluation of drug susceptibilities of Babesia divergens isolates. Antimicrob Agents Chemother. 1998 Apr;42(4):818-20. doi: 10.1128/AAC.42.4.818. PMID: 9559789; PMCID: PMC105548. 11: Lee SW, Woo CW, Kim JG. Selectivity of oxomemazine for the M1 muscarinic receptors. Arch Pharm Res. 1994 Dec;17(6):443-51. doi: 10.1007/BF02979123. PMID: 10319156. 12: Maurer H, Pfleger K. Identification of phenothiazine antihistamines and their metabolites in urine. Arch Toxicol. 1988;62(2-3):185-91. doi: 10.1007/BF00570138. PMID: 2904251. 13: Pérez EH, Santos LR. A oxomemazina (6847 RP) nas dermatites pruriginosas [Oxomemazine (6847 RP) in dermatitis pruriginosa]. Hospital (Rio J). 1969 Feb;75(2):703-14. Portuguese. PMID: 5311223. 14: De Groote J, Gomand L, Van de Mierop L. Klinische studie van oxomemazine in de gastro-enterologie: meer bepaald in de oesophago-gastrische patologie [Clinical studies with oxomemazine in gastroenterology: more specifically in esophago-gastric pathology]. Tijdschr Gastroenterol. 1966;9(4):371-8. Dutch. PMID: 5336251. 15: Lecomte J. Antagonisme comparé de l'oxomémazine et de la prométhazine sur l'hypotension artérielle histaminique du rat [Comparative antagonism of oxomemazine and promethazine on histaminic arterial hypotension in rats]. C R Seances Soc Biol Fil. 1966;160(5):1108-10. French. PMID: 4225083. 16: Alison M. Essais thérapeutiques chez l'enfant et particulièrement chez le nourrisson d'un nouveau sirop bechique, expectorant, à base d'oxomémazine [Therapeutic trials in children and particularly in infants of a new expectorant cough syrup with oxomemazine base]. J Med Lyon. 1965 Oct 20;46(85):1683-6. French. PMID: 5854603. 17: Chapuis, Dalmais, Belpois, Meunier. L'Oxomémazine (nouvel antihistaminique). Son intérêt en médecine générale [Oxomemazine (new antihistaminic). Its value in general medicine]. Lyon Med. 1965 Sep 19;214(38):413-6. French. PMID: 4379009. 18: HERXHEIMER H, STRESEMANN E. THE EFFECT OF SOME NEW ANTIHISTAMINES ON THE ANAPHYLACTIC MICROSHOCK OF THE GUINEA-PIG. Br J Pharmacol Chemother. 1963 Dec;21(3):414-8. doi: 10.1111/j.1476-5381.1963.tb02008.x. PMID: 14110740; PMCID: PMC1703885.